FDA Approves First Non-Antipsychotic Drug for Agitation in Alzheimer’s

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Alzheimer’s disease is a brain disorder that causes memory loss and behavioral changes, including severe agitation.

First non-antipsychotic option.Previously, doctors had to rely on antipsychotic drugs for agitation, which carry serious risks like stroke and death in older patients. Auvelity offers a safer alternative that targets agitation without those same dangers.
Addresses a major distress source.Agitation in Alzheimer’s includes verbal outbursts and physical aggression that harm quality of life for patients and caregivers. This approval gives families a new tool to manage these behaviors, reducing suffering on both sides.
Repurposes an existing drug.Auvelity was already approved for major depressive disorder, so its safety profile is well understood. This speeds up patient access compared to developing an entirely new medication from scratch.
Targets a previously unmet need.Before this approval, no medication was specifically approved for agitation in Alzheimer’s. Doctors now have a dedicated treatment option, rather than relying on off-label drugs with uncertain benefits.

The U.S. Food and Drug Administration has approved the first ever non-antipsychotic medication specifically for agitation in Alzheimer’s disease, offering a new option for one of the most distressing symptoms of dementia. The decision expands the use of Auvelity, a drug already approved for major depressive disorder, to treat the agitation that affects many patients as their condition progresses.

Agitation in Alzheimer’s includes excessive motor activity, verbal outbursts, and physical aggression. The FDA noted that these behaviors can significantly harm quality of life for both patients and caregivers. The approval is based on two randomized trials. In the first, a five week study, patients taking Auvelity showed significantly greater improvement in agitated behaviors compared to placebo, based on caregiver reports. In the second trial, patients who responded to the drug were randomly assigned to continue treatment or switch to placebo. Those who stayed on Auvelity had a significantly longer time before their agitation symptoms returned.

Auvelity is taken as a rapid onset extended release tablet. It works on two brain targets: NMDA and sigma 1 receptors. This dual action helps reduce both agitation and depression in older adults with dementia. The FDA advises healthcare providers to monitor blood pressure, screen for a history of bipolar disorder, and check for interactions with other drugs before prescribing. Common side effects include dizziness, headache, diarrhea, dry mouth, and drowsiness. The drug also carries risks of seizures, elevated blood pressure, and increased suicidal thoughts in younger adults, so monitoring is required.

The approval marks a meaningful advance because it provides an alternative to antipsychotic medications, which can cause drowsiness and other serious side effects in elderly patients. Experts note that Auvelity is generally better tolerated and does not carry the same heart risks as many antipsychotics. The FDA hopes this new option will offer meaningful relief to families navigating the challenges of Alzheimer’s disease, especially as the condition progresses and agitation becomes more difficult to manage.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.